Category Medicine and Healthcare
Press Release
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure (IF) indications Presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID) Read More
Press Release
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs Jaguar expects to make Neonorm Dog available through both Amazon and Chewy Read More
Press Release
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID Read More
Press Release
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting, lab processing, and surgeries-potentially setting a new standard of care for knee cartilage repair Read More
Press Release
Imagene AI and Tel Aviv Sourasky University Medical Center (Ichilov) Build Clinical AI Infrastructure to Advance Precision Oncology and Biopharma R&D
The collaboration will enable the development, validation, and application of advanced AI technologies to identify clinically meaningful patient subgroups, support biomarker-driven clinical trials, and create a platform for biopharma partnerships advancing innovation and personalized medicine. Read More
Press Release
New Survey Reveals Wide Gap Between Dentists' and Hygienists' Confidence in Hygiene Appointments
72% of dentists say they're "very confident" hygiene appointments meet best-practice standards; only 29% of hygienists agree, according to a new survey of dental professionals from Alta Voice Read More
Press Release
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production GelrinC®, which is approved for sale in the European Union, is pioneering knee cartilage repair with an off-the-shelf cell-free hydrogel implant Read More
Press Release
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives Read More
Press Release
Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation
Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical trial, as a predefined endpoint New peer-reviewed data published in the scientific journal Cartilage uses the complete set of follow-up data from GelrinC's Phase II study, which establishes GelrinC as a leader in long-term durable cartilage repair, using objective, quantitative MOCART assessment to demonstrate morphologic outcomes that consistently outperform other treatment modalities The data presented by Regentis show that two years after treatment, the repaired cartilage appears very close to normal healthy cartilage, highlighting the long-term durability of GelrinC and reinforcing its competitive superiority in the cartilage repair landscape GelrinC is already approved in Europe and currently in a pivotal Phase III U.S. FDA study Read More
Press Release
LiveForeverHealth Launches Full-Stack Hormone & Telemedicine Franchise Model
LIVE FOREVER HEALTH™ UNVEILS FULL-STACK HORMONE & TELEMEDICINE FRANCHISE MODEL, PIONEERING LONGEVITY CARE IN ALL 50 STATES The Specialized Health Leader Offers a Turnkey System for Entrepreneurs to Capitalize on the Booming $27 Billion Hormone Replacement Market with Proven Clinical Protocols and Transparent Pricing. Introducing the News: The Core Announcement Read More
Press Release
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support BUZZ BOMB™ will power Ashley's elite training, recovery, and lifestyle needs with its best-in-class product In partnering with Aspire's BUZZ BOMB™ brand, Ashley joins a decorated athlete and fitness trainer roster fueled by the brand's industry-leading commitment to innovation Read More
Press Release
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing Read More
Press Release
Synadentix Reviews (URGENT REPORT) New Oral Microbiome Research Reveals What This Enzyme Supplement Really Does
A science-driven 2025 investigation into Synadentix's enzyme technology, hydroxyapatite repair matrix, oral microbiome modulation, and real-world results reported by over 12,000 users Read More
Press Release
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited approval pathway Read More
Press Release
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placebo Read More
Press Release
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the European Union, subject to authorization by the European Commission Read More
Press Release
President Trump's Cannabis Decision Is Coming - And Why MMJ International Holdings Wins Either Way
12 Month Timeline - How Cannabis Rescheduling Actually Takes Effect Announcement President signals intent or issues executive direction DEA Rulemaking DEA drafts proposed rule; public notice and comment period Final DEA Rule DEA reviews comments and issues final scheduling decision Federal Register Publication Legal effective date (often immediate or 30-60 days later) No Federal Register publication = no change in law Read More
Press Release
Sugar Defender Reviews (2025 Clinical Report) Evidence, Metabolic Research, Complaints & Real Outcomes After 90 Days
A data-backed analysis of Sugar Defender, including updated metabolic research, verified user trends, ingredient science, complaint patterns, safety findings, clinical plausibility, and whether this popular blood sugar supplement truly works in 2025. Read More
Press Release
